Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Non-Current Liabilities (2018 - 2025)

Bicycle Therapeutics' Total Non-Current Liabilities history spans 8 years, with the latest figure at $106.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 34.48% year-over-year to $106.6 million; the TTM value through Dec 2025 reached $106.6 million, down 34.48%, while the annual FY2025 figure was $106.6 million, 34.48% down from the prior year.
  • Total Non-Current Liabilities reached $106.6 million in Q4 2025 per BCYC's latest filing, down from $144.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $229.7 million in Q2 2023 to a low of $78.9 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $150.4 million, with a median of $143.4 million recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: soared 106.49% in 2021, then plummeted 34.48% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $130.3 million in 2021, then grew by 4.41% to $136.0 million in 2022, then soared by 61.65% to $219.8 million in 2023, then dropped by 26.0% to $162.7 million in 2024, then crashed by 34.48% to $106.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Total Non-Current Liabilities are $106.6 million (Q4 2025), $144.4 million (Q3 2025), and $162.1 million (Q2 2025).